Myasthenia Gravis Treatment Guidelines
Myasthenia gravis is estimated to affect up to 60 000 Americans and over 700 000 public global, though rates are probable even higher because the disease remains under diagnosed. The prognosis for patients with MG has enhanced in recent years, due mostly to the increasing use of immunomodulating therapies.
To develop consensus-based Myasthenia Gravis Treatment guidelines planned for clinicians global, a task force appointed by the Myasthenia Gravis Foundation of America of which Dr Sanders is a co-chair – selected a panel of 15 MG experts to “represent the breadth of knowledge and experience and a wide variety of opinions from Myasthenia Gravis experts worldwide,” according to the paper. The specialists first voted and agreed upon beginning definitions of key concepts, including treatment goals, minimal manifestations, ocular MG, remission, impending and manifest crisis, and refractory Myasthenia Gravis. The panel then met to identify 7 treatment topics to address and to develop initial guidance statements.
After some rounds of anonymous email voting and modifications based on input from panel members, consensus guidelines were developed for the following areas: symptomatic and immunosuppressive Alternative Treatment for Myasthenia Gravis, IV immunoglobulin and plasma exchange, treatment of impending and manifest myasthenic crisis, thymectomy in MG, juvenile MG, Myasthenia Gravis connected with antibodies to muscle-specific tyrosine kinase, and management of MG in pregnancy.